PARP inhibitor CVL218 with other drugs for advanced solid tumors
Part of Cancer, Digestive system, Skin clinical trials.
This trial tests a new PARP inhibitor pill (CVL218) combined with other treatments for advanced solid tumors, especially in people with certain gene changes. It may be an option if you have had only one prior treatment or none.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have advanced or metastatic solid tumor cancer (like triple-negative breast cancer, stomach cancer, or colorectal cancer).
- You have tried no more than 1 standard treatment, or there is no standard treatment for you.
- For the second part of the study, your tumor must be PD-L1 positive (CPS≥1) or have a harmful mutation in BRCA, PALB2, ATM, or CHEK2.
- You have not had chemotherapy, radiation, or other cancer treatments in the last 4 weeks (or longer for some drugs).
- You have not had major surgery or taken strong steroids in the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment (CVL006 plus other drugs) in people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if the combination can shrink tumors and help patients live longer.
This early-phase study tests XL309 (and sometimes a mix of XL309 with another treatment) in people whose advanced solid tumors have specific DNA-repair gene changes, such as BRCA1/2 or other HRR-related changes. It aims to see how well the drug works and what dose is safest for these cancers.
This study tests a new drug, CVL006, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective for certain types of cancer, such as non-small cell lung cancer or tumors with high genetic mutations (MSI-H/dMMR or TMB-H).
This study tests a combination of two experimental cancer-fighting drugs (CVL006 and 9MW2821) in patients with advanced solid tumors, particularly head and neck cancer. The goal is to see if this combination can slow tumor growth and improve outcomes in patients whose cancers have not responded to standard treatments.
This trial tests a new drug called IMP1734 for people with advanced breast, ovarian, or prostate cancer that has a specific genetic change called an HRR mutation. The drug targets a protein called PARP1 to try to stop cancer cells from repairing themselves.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.